Milo Biotechnology

Milo Biotechnology is developing novel therapies based on follistatin, a protein that increases muscle mass and strength. Milo is targeting rare neuromuscular diseases, initiating a Phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis.
Read the Case Study

Funding: North Coast Opportunity Fund, JumpStart, Rev1 Ventures

Stage: Clinical

News: Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis